Telomir Pharmaceuticals IncNASDAQ:TELO
- LAST PRICE6.8650
- TODAY'S CHANGE (%)0.0651 (0.9574%)
- Bid / Lots4.8000/ 1
- Ask / Lots6.8600/ 1
- Open / Previous Close6.7700 / 6.7999
- Day Range
- 52 Week Range
- Volume23,964
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TELO |
|---|---|---|
| 09:32 ET | 110 | 6.77 |
| 09:43 ET | 100 | 6.735 |
| 09:56 ET | 100 | 6.6776 |
| 09:59 ET | 100 | 6.6 |
| 10:14 ET | 100 | 6.72 |
| 10:17 ET | 985 | 6.71 |
| 10:28 ET | 500 | 6.7 |
| 10:44 ET | 100 | 6.645 |
| 11:00 ET | 2241 | 6.555 |
| 11:02 ET | 1400 | 6.51 |
| 11:04 ET | 400 | 6.5695 |
| 11:06 ET | 300 | 6.5839 |
| 11:08 ET | 482 | 6.6 |
| 11:26 ET | 100 | 6.52 |
| 11:27 ET | 300 | 6.5677 |
| 11:29 ET | 6212 | 6.41 |
| 11:36 ET | 1186 | 5.91 |
| 11:58 ET | 200 | 6.1036 |
| 12:05 ET | 100 | 6.22 |
| 12:16 ET | 100 | 6.29 |
| 12:43 ET | 300 | 6.19 |
| 12:48 ET | 300 | 6.19 |
| 01:01 ET | 500 | 6.1764 |
| 01:26 ET | 100 | 6.11 |
| 01:44 ET | 100 | 6.315 |
| 01:50 ET | 211 | 6.3857 |
| 02:09 ET | 192 | 6.385 |
| 02:13 ET | 100 | 6.395 |
| 02:29 ET | 1918 | 6.23 |
| 02:33 ET | 100 | 6.19 |
| 02:45 ET | 100 | 6.395 |
| 03:12 ET | 100 | 6.39 |
| 03:18 ET | 899 | 6.4 |
| 03:25 ET | 100 | 6.41 |
| 03:36 ET | 100 | 6.865 |
Apr 16, 2024
Apr 2, 2024
Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024, from 8:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
Mar 29, 2024
UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines, from 4:44PM ET on Friday Mar 29, 2024 by Dow Jones
4:44PM ET on Friday Mar 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Telomir Pharmaceuticals Inc | 203.3M | -14.3x | --- |
ASP Isotopes Inc | 168.3M | -6.9x | --- |
Biostem Technologies Inc | 147.6M | 0.0x | --- |
Hongchang International Co Ltd | 115.5M | -258.8x | --- |
Jasper Therapeutics Inc | 307.3M | -3.3x | --- |
Cellectar Biosciences Inc | 97.7M | -0.9x | --- |
Company Information
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Company’s BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.
Contact Information
- Headquarters
- 900 West Platt Street, Suite 200TAMPA, FL, United States 33606
- Phone
- 813-864-2562
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Christopher Chapman
- Chief Financial Officer, Treasurer, Secretary
- Nathen Fuentes
- Independent Director
- Craig Eagle
- Independent Director
- Michael Jerman
- Independent Director
- Brad Kroenig
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $203.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.48 |
Book Value | $0.12 |
P/E Ratio | -14.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
